A LTHOUGH the discovery of angiotensin (angiotonin or hypertensin) was reported independently in 1939 by Page and Helmer1 in this country and by Braun-Menendez and co-workers2 in Argentina, its structure was not described until 1956 and its active principle not synthesized until 1957. Angiotensin is known to exist in at least two forms, angiotensin I and angiotensin II. While the decapeptide angiotensin I does not have vasoconstrictor properties, the octapeptide, angiotensin II, formed by action of the converting enzyme on angiotensin I, is an extremely powerful vasoconstricting agent. 3 4 Circulatory effects of synthetic angiotensin in animals have been extensively studied by Page and his associates and other investigators.5-7 Many workers have reported the hemodynamic effects of various angiotensin preparations in normotensive subjects. [8] [9] [10] [11] [12] [13] [14] However, there has been scanty information in the literature regarding the effects of angiotensin on pulmonary circulation and ventricular function in man. It is the purpose of this paper to report these effects of angiotensin II in 16 normotensive patients. Data of hemodynamic studies in eight anesthetized dogs Presented in part at the Thirty-third Annual Scientific Sessions of the American Heart Association, St. Louis, Missouri, October 21-23, 1960. 1326 were also included for delineation of some of the findings in human studies.* Clinical Material and Method
Human Studies Sixteen patients with normal systemic and pulmonary artery pressures were studied. There were 11 males and five females whose ages ranged from 17 to 60 years. None of these patients had clinical or physiologic evidence of aortic stenosis, mitral valvular disease, or intracardiac shunts.
Right heart catheterization was performed in the usual manner. index; TM, mean transit time from pulmonary artery to femoral artery; Ta, circulation time from femoral artery to femoral artery; "CBV", "central" blood volume or dilution volume from pulmonary artery to femoral artery; TBV, total blood volume; SE, standard error of mean; p indicates the probability that difference as large as that observed will occur by chance-a difference with a chance probability of 0.05 or less is considered to be significant; NS, not significant. the same manner as previously described. Determination of cardiac output and measurements of pressures were carried out repeatedly during angiotensin infusion with or without rapid blood infusion. Table 3 shows the values of various parameters in a given dog by averaging two or more determinations obtained during a certain circulatory state, (i.e., blood or angiotensin infusion).
In another three dogs pressure and flow measurements were first made during a control period as well as during angiotensin infusion, with graded doses ranging from 0.1 tig./Kg./iiiin. to 5 pig./ Kg./min. In two of these dogs, after angiotensin infusion was discontinued, single or multiple doses of hexamethonium ( 
Results

Human Studies
The results are summarized in tables 1 and 2.
During angiotensin infusion there were statistically significant increases in femoral Arterial, pulmonary wedge, and pulmonary arterial pressures. No statistically significant change was observed in cardiac output, heart rate, and stroke volume. For the whole group, there was a parallel increase in oxygen consumption and in the arteriovenous oxygen difference. However, significant increase in oxygen consumption, i.e., more than 13 per cent of the control value, was noted in only six patients. The cause of this increase was not apparent.
Total systemic, total pulmonary, and pulmonary vascular resistances and the left ventricular work against pressure were all statistically increased. In most cases, however, the magnitude of increase in the pulmonary vascular resistance was small.
In seven patients in whom right ventricular pressure was measured, there was a consistent rise in both systolic and diastolic pressures directly proportional to the magnitude of elevation of pulmonary artery pressure. In six of these seven patients the right ventricular work against pressure was also increased.
In most instances there was a slight prolongation in the mean transit time from the pulCirculation, Volume reached its maximum within 5 minutes of infusion.
During angiotensin infusion in nine of the 16 patients there was a significant increase in the upstroke time of the femoral arterial pressure tracing associated with the presence of gn 4nacrQtic notch close to the top ( fig. 2) 6 ).
As shown in table 3, rapid blood infusion caused an increase in cardiac output, stroke volume, left atrial and pulmonary arterial pressures, and left ventricular stroke work. The average pressure gradient from the pulmonary artery to the left atrium was widened. There was a slowing in heart rate but no appreciable change in the systemic arterial pressure. In contrast, angiotension infusion produeed anl increase in systemic arterial pressure and left ventricular stroke work, but no change in cardiac output, stroke volume, and heart rate. A slight increase in both left atrial and pulmonary arterial pressures was observed, but compared with the control value there was no appreciable change in the average pressure gradient from the pulmonary artery to the left atrium.
When both blood and angiotensin were infused simultaneously, the effects were additive, manifested particularly by the increase in left ventricular stroke work and left atrial and pulmonary arterial pressures. Representative left and right ventricular function curves during blood infusion with or without angiotensin are depicted in figure 7 .
Discussion
Angioteiisin infused intravenously to both men and dogs is a very powerful pressor agent.
It produces a prompt increase in total systemic resistance and systemic arterial pressure, most likely as a result of systemic arteriolar constriction.
During angiotensin infusion the consistent rise in the pulmonary wedge or left atrial pressure reflects a rise in the left ventricular diastolic or filling pressure. The increased left ventricular filling pressure accompanied by the alteration of systemic arterial pressure tracing, which was characterized by a prolonged upstroke time and the presence of an anacrotic notch, strongly suggests an increase in the "'left ventricular'" resistance. Such changes are frequently observed in patients with aortic stenosis.
It should be pointed out that in human studies, although there was a direct relationCirculation, Volume ship between the increment in the respective ventricular stroke work and diastolic pressure, the data did not truly represent ventricular function curves either during the control period or during the period of angiotensin infusion. At best, they demonstrated that during angiotensin infusion there was an increase in the ventricular work at a higher level of filling, pressure. We were able to obtain ventricular function curves in dogs, however, during both the control period and the period of angiotensin infusion by varying the left and right ventricular filling pressures. It was shown that the ventricular function curve during angiotensin infusion was shifted to the left and above that during the control period. In other words, more external work was performed at any given filling pressure during angiotensin infusion than during the control period. Thus angiotensin indeed caused an increase in the myocardial contractility as well as in the ven- At that time there was no means to measure the pulmonary arterial and intracardiac pressures; therefore, it was not possible to correlate the increment in venous pressure with that in right ventricular stroke work. In the present study, a parallel increase in both right ventricular diastolic pressure and stroke work was observed in six of seven patients in whom the right ventricular and pulmonary arterial pressures were measured. One would anticipate similar findings in the study made by Wilkins and Duncan, should such measurements be available.
In animal experiments, when larger doses of angiotensin (more than 1 ug./Kg./min.) were given, there was a further rise in the left atrial pressure, with no appreciable change in the left ventricular stroke work. This may imply that in animals angiotensin given in smaller doses had its predominant action on myocardium, whereas with larger Left and right ventricular function curves during blood infusion with or without angiotensin after step-wise elevation of the reservoir. The prolongation of the total circulation time from femoral artery to femoral artery was more striking than that of the mean transit time from the pulmonary artery to the femoral artery. This difference strongly 
Summary and Conclusions
The effects of angiotensin (Hypertensin II CIBA) given by intravenous infusion on pulmonary circulation and ventricular function were studied in 16 normotensive patients and eight anesthetized dogs.
During angiotensin infusion the following changes were observed: (a) an increase in pressures in both systemic and pulmonary circuits and four cardiac chambers, and variable change in pulmonary artery-pulmonary wedge (or left atrial) pressure gradient; (b) slightly decreased or unchanged cardiac output and stroke volume; (c) significantly increased total systemic and total pulmonary resistances; (d) significant increase in stroke work of both ventricles; (e) significant prolongation in the circulation time from femoral artery to femoral artery and slight prolongation in mean transit time from pulmonary artery or right heart to the femoral artery and, (f) no significant alteration in total or "central'" blood volume.
It is concluded that (a) angiotensin is a very powerful vasopressor agent and has its action primarily on the systemic circulation; (b) in the compensated human and canine hearts it also increases myocardial contraetility and ventricular function; and (c) in patients without mitral valvular lesions or intracardiac shunts the hemodynamic changes in the pulmonary circulation are mostly secondary.
